Navigation Links
Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:9/5/2007

- Company Will Present Seven Posters and sponsor Satellite Symposium at Key

Scientific Gathering at McCormick Place in Chicago, September 17

- 20 -

CHICAGO, Sept. 5 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), will present seven posters on selected cethromycin therapeutic studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) at McCormick Place in Chicago, September 17 - 20. ICAAC, a key scientific event expected to attract more than 12,000 scientists from around the world, is a gathering of leading researchers and clinicians to discuss important themes and present the newest treatment advances in infectious disease. The Advanced Life Sciences booth, #643, will be located in Hall D in the Lakeside Center at McCormick Place.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050428/CGTH039LOGO)

The Advanced Life Sciences poster presentations will discuss in vitro activity of cethromycin against key susceptible and resistant pathogens involved in community acquired pneumonia (CAP) as well as safety data in certain special clinical populations. Along with collaborators such as the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Eurofins Medinet, Micromyx and Battelle, the Company will present data demonstrating the potency of cethromycin against pathogens involved in bioterrorism.

In addition, Advanced Life Sciences is sponsoring a satellite symposium entitled "Drug Resistant CAP, Current and Future Treatments: Best Practices for Prevention and Management". The panel, moderated by Gerald Donowitz, M.D., will feature presentations by Richard Wunderink, M.D., Joseph Blondeau, Ph.D. and B. Joseph Guglielmo, Jr., Pharm.D., all thought leaders in the field of infectious disease and microbiology. The satellite symposium is supported by Advanced Life Sciences through an unrestricted educational grant to the American Society for Microbiology and Conexus Health.

Symposium and Presentation Schedule

Monday, September 17, 7:00 p.m. Central Daylight Time, Room E354A

-- Satellite Symposium: Drug Resistant CAP, Current and Future Treatments:

Best Practices for Prevention and Management

Tuesday, September 18, 11:15 a.m. Central Daylight Time, Room E253D

Poster Session 222: Pathogenesis and Therapeutics in Agents of

Bioterrorism

-- Poster: Poster B-2031: Efficacy of Cethromycin Against a Lethal

Inhalation Anthrax Challenge in Rhesus Macaques

Wednesday, September 19, 12:15 p.m. Central Daylight Time, Hall D

Poster Session 176: Macrolides, Ketolides, Bicyclolides and Quinolones

-- Poster E-1633: Assessment of In Vitro Activity of Cethromycin Against

Telithromycin-resistant Strains of Streptococcus pneumoniae

-- Poster E-1632: Assessment of In Vitro Activity of Cethromycin Against

Strains of Streptococcus pneumoniae

-- Poster E-1631: Assessment of In Vitro Activity of Cethromycin Against

Strains of Haemophilus influenzae

-- Poster E1634: Antimicrobial Activity of Cethromycin, a Novel Ketolide,

Tested against a Diverse Collection of Francisella tularensis Strains

Thursday, September 20, 9:00 a.m. Central Daylight Time, Hall D

Poster Session 82: New Drug Pharmacokinetics

-- Poster A-797: Evaluation of the Safety and Pharmacokinetics of

Cethromycin Following Administration of Multiple Doses to Subjects with

Severe Renal Impairment

-- Poster A-796: Evaluation of the Safety and Pharmacokinetics of

Cethromycin Following Administration of Single and Multiple Doses to

Subjects with Mild or Moderate Chronic Hepatic Insufficiency

About ICAAC

The American Society for Microbiology (ASM) is hosting the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), which will be held in Chicago, Illinois, September 17 - 20, 2007. More than 12,000 physicians, researchers and other healthcare professionals from around the globe gather each year at ICAAC to foster worldwide solutions to the challenges of infectious diseases.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel once-a-day antibiotic in late-stage clinical development for the treatment of respiratory tract infections.

Forward-Looking Statements

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
6. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
7. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
8. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
9. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
10. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
11. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... Kitov Pharmaceuticals ... late-stage drug development, today announced the completion of ... batches required for registration of KIT-302 with the ... Kitov,s announcement in December 2015, that ... primary efficacy endpoint. "We are fortunate ...
(Date:5/26/2016)... May 26, 2016 A key ... is the emergence of new treatments. Cardax, a development ... osteoarthritis treatment. The therapy is expected to fulfil large ... UK is conducting studies to develop new treatments for ... the genes involved in osteoarthritis are being investigated, and ...
(Date:5/25/2016)... FDA 510(k) clearance covers Confocal Miniprobes ... and surgical applications Mauna Kea Technologies ... multidisciplinary confocal laser endomicroscopy (CLE) platform, today announced ... the 12 th 510(k) clearance from United ... FDA clearance covers Confocal Miniprobes indicated for use ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 27, 2016 , ... An educational campaign aimed at everyone ... courtesy of awareness-driven celebrities and thought leaders. It also provides insight to the ... leaders such as Bioness. , As patients feel increasingly concerned about the ...
(Date:5/27/2016)... ... May 27, 2016 , ... Beleza Medspa has initiated ... regulations. This is the first time that Coolsculpting is being used for for ... six months to ensure they meet the prescribed body-fat standard, measured by the circumference-based ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and ... stories, which come courtesy of leaders in the nursing and health care industry. It ... advocates and associations—namely Abilene Christian University. , As the nursing industry is coming ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... trusted name in the pharmaceutical, medical and food industries. Aside from its GMP ... certification (SIC), providing proof of successfully certified products, services and staff. , Validation ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways ... and Sausage Council (NHDSC) suggests that Americans prefer their dogs straight off the grill. ... say grilling is their favorite way to cook a hot dog, far outpacing other ...
Breaking Medicine News(10 mins):